Home/Pipeline/ABBV-400

ABBV-400

Advanced Solid Tumors

Phase 1RecruitingNCT05029882

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Recruiting

Company

AbbVie

About AbbVie

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

View full company profile

Therapeutic Areas

Immunology Oncology Neuroscience Eye Care Virology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active